The molecules of life, DNA, replicate with astounding precision, yet this process is not immune to mistakes and can lead to mutations.
Contract manufacturer CordenPharma, recently tapped in a German push to earmark mRNA vaccine capacity, is getting a new owner.
Biogen’s yearlong struggle with the controversial FDA approval and launch of Aduhelm has culminated in a deep overhaul reaching all the way to the CEO.